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Neonatal diabetes mellitus (NDM) is a rare metabolic disorder, affecting approximately 1 in 500,000 live births. The
management of NDM is challenging, as the benefits of controlling hyperglycemia must be balanced with the risks
of iatrogenic hypoglycemia. NDM occurs in both permanent and transient forms, which have been genetically and
phenotypically well characterized. Herein, we present the previously unreported combination of transient NDM
(TNDM) and congenital diaphragmatic hernia (CDH). In addition to reviewing the management and genetics of
NDM we discuss the potential for overlapping genetic or embryologic abnormalities to explain the concurrence of
CDH and NDM.
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Neonatal diabetes mellitus (NDM) is a rare disorder of
glucose metabolism (affecting 1 in 500,000 live births)
and may be either transient or permanent [1]. Affected
neonates frequently present with hyperglycemia, intra-
uterine growth retardation, and variable degrees of dehy-
dration. Despite the relative severity of insulin
deficiency, ketoacidosis is uncommon. Treatment with
exogenous insulin is required to promote normal growth
and avoid acute and sub-acute complications associated
with severe hyperglycemia.
Transient NDM (TNDM) is associated with over-
expression of paternal genes on chromosome 6 that re-
duce the capacity of the β cell to release insulin. TNDM
is characterized by resolution of hyperglycemia by
18 months of age though 40-50% of patients with
TNDM experience a recurrence of diabetes in adoles-
cence or early adulthood [1,2]. Permanent NDM
(PNDM) is associated with mutations of the β cell ATP-
sensitive potassium channel which disable the β cell’s
ability to depolarize and release insulin [3].* Correspondence: hallemj@peds.ufl.edu
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reproduction in any medium, provided the orCongenital diaphragmatic hernia (CDH) occurs in ap-
proximately 1 in 2,500 children and results from a devel-
opmental defect in the diaphragm that allows abdominal
viscera to penetrate the chest [4]. Because the herniating
spleen, liver, and intestines may compress lung tissue
during critical periods of lung organogenesis, CHD
results in varying degrees of irreversible pulmonary
hypoplasia. Approximately 50% of CDH cases are asso-
ciated with chromosomal abnormalities or congenital
malformations including gut malrotation, umbilical her-
nia, hydronephrosis, cardiac defects, and type 1 diabetes
[2,4,5]. However, the combination of CDH and TNDM
has not previously been reported.
Given the unlikely coincidence of CDH and TNDM
we explore the potential for a common genetic or em-
bryologic etiology of these two diagnoses.Case presentation
A 2.4 kg female infant was born at 38 weeks gestation to
a 28-year-old primigravida via elective cesarean section.
Birth weight was 2401 grams (2nd percentile), length
was 48 cm (29th percentile), and head circumference
was 34 cm (32nd percentile). The baby was diagnosed
with a left sided CDH at 14 weeks gestation by routine
prenatal ultrasound. Due to the prenatally diagnosedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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os, and placed on intravenous hyperalimentation provid-
ing a glucose infusion rate (GIR) of 8 mg/kg/min. Al-
though her blood glucose concentration was normal at
birth (103 mg/dl), she developed marked hyperglycemia
(493 mg/dl) at 9 hours of life.
Family history was notable for neonatal diabetes in the
paternal grandmother that resolved within 2 months.
She developed adult-onset diabetes in the 4th decade of
life despite a lean body habitus.
Pertinent physical findings in our patient included shal-
low supraorbital ridges, relatively prominent eyes, a mildly
protruding tongue with micrognathia, mild pectus excava-
tum, and bilateral accessory nipples. She had a normal
cranial shape, no central forehead nevus flammeus, nor-
mal ears without pits, and no evidence of limb asymmetry.
She had normally developed female genitalia and an
otherwise normal skin exam (See Additional file 1).
Initial laboratory evaluation revealed negative urine
ketones, undetectable serum insulin concentration (< 0.5
mcIU/ml), and a low serum C-peptide concentration
(0.2 ng/mL). Arterial blood gas and electrolyte mea-
surements demonstrated a non-anion gap metabolic
acidosis with an elevated serum lactate (2.47 mmol/L).
A thoracoabdominal ultrasound performed on day of
life 2 revealed a pancreas without definite abnormality,
but bowel gas prevented optimal delineation of the
organ.
Initial management included decreasing the GIR, but a
concomitant decrease in blood glucose was not observed.
Over the next 6 hours, she was treated with 3 subcutane-
ous injections of 0.5 units rapid-acting insulin analog,
which failed to normalize her blood glucose concentra-
tion. A continuous intravenous infusion of regular insulin
was started with an initial rate 0.04 units/kg/hour. Six
hours after initiating the insulin infusion, her blood glu-
cose concentration fell below 200 mg/dl and insulin was
briefly discontinued. Her blood glucose concentration
gradually increased to 230 mg/dl over the next 6 hours,
and a simultaneous serum insulin level was <0.5 mcIU/ml.
Therapy with continuous intravenous insulin was resumed
at 0.03 units/kg/hour. The rate of the infusion was then
titrated to achieve blood glucose concentrations between
200–300 mg/dl. The maximum rate of insulin administra-
tion was 0.12 units/kg/hour.
On day of life 4, blood glucose concentrations were
stable on 0.02-0.05 units of insulin per kg per hour and
our patient underwent surgical repair of her CDH. At
repair she had a moderately severe hernia with small
bowel, colon, stomach, and spleen in the left chest. Her
CDH was associated with a 50% loss of normal dia-
phragm and was repaired with a patch. Her left lung was
approximately 30% of normal size. She transitioned to
oral feeds approximately one week after the operation.In preparation for discharge home, our patient was
transitioned to continuous subcutaneous insulin infusion
(SCII) therapy with rapid-acting analog diluted 10-fold.
A single basal rate of 0.5 units/hr of U-10 insulin was
programmed in the pump (total daily dose 1.2 units).
Blood glucose was monitored every 3 hours (typically
before breastfeeding) and a correction bolus of insulin
was given for blood glucose values greater than 350 mg/dL.
Use of a continuous glucose monitoring system was consid-
ered, but our patient had so little subcutaneous fat that sen-
sor placement was deemed impossible. Upon discharge, her
insulin requirement quickly waned, and the insulin was dis-
continued at 7 weeks of age.
At her three-month visit, she was thriving, with a
weight of 4004 grams, and a hemoglobin A1c of 4.7%.
Comparative genomic hybridization microarray analysis
using a 180 K oligonucleotide array platform revealed a
389 K micro-duplication in region 6q24.2, which
includes the paternally expressed PLAGL1 (pleomorphic
adenoma of the salivary gland gene like 1) and HYMAI
(hydatidiform mole associated and imprinted [non-
protein coding]) genes known to be associated with
TNDM. An additional gene, PHACTR2 (phosphatase
and actin regulator 2), also maps within the same de-
letion boundary, though presumably it is not related
to the problems in our patient. The same duplication
was found in her father, who did not have neonatal
diabetes and who does not have considerable hyper-
glycemia, as evidenced by a normal HbA1c (personal
communication, MJ Haller).
The same micro-duplication in region 6q24.2 was dis-
covered in our patient’s paternal uncle and his unborn
child. Amniocentesis demonstrated the presence of the
mutation in our patient’s first cousin. At birth, the baby
boy followed a very similar course to our patient. He
was small at birth, weighing 1710 grams at 34 weeks ges-
tation (5th percentile). Hyperglycemia developed in the
first 24 hours of life, and insulin therapy was required
for 6 weeks before resolution occurred.
Discussion
The management of infants with NDM remains challen-
ging, given the need to balance the benefits of normal
glycemia with the risks of recurrent hypoglycemia in
infants. In our experience, continuous subcutaneous in-
sulin infusion (CSII) therapy provides optimal equipoise
in managing children with NDM. While there are lim-
ited outcomes data to drive evidence based treatment
recommendations for NDM, several case series have
been published. Tubina-Rufi et al. reported on their
experiences in managing NDM over 18 years, and found
CSII therapy to be most effective in safely managing dia-
betes in newborns requiring insulin for more than
15 days [6].
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expression of the paternally inherited PLAGL1 and
HYMAI genes at the 6q24 locus. PLAGL1 is a zinc fin-
ger DNA binding protein with tumor suppressor activity,
and overexpression of this gene has been shown to ar-
rest β cell division and induce apoptosis. HYMAI shares
a promoter region with PLAGL1, and methylation of
this promoter on the maternal allele results in sole ex-
pression of the paternally inherited allele in most tissues;
HYMAI is a non-coding RNA gene whose function is
unknown. Over-expression of these genes can occur as a
result of uniparental disomy of chromosome 6, duplica-
tion of 6q24 of the paternal allele, or hypomethylation of
the maternal PLAGL1/HYMAI differentially methylated
region [7,8].
PNDM is most commonly caused by mutations in the
KCNJ11 and ABCC8 genes, which encode the Kir6.2,
and SUR1 subunits of the β cell ATP-sensitive potassium
channel, respectively [3]. This potassium channel is con-
stitutively open, but closes in response to increased
intracellular ATP levels that occur as a consequence of
hyperglycemia. When the channel closes, β cell
depolarization occurs, and insulin is released. A gain-
of-function mutation in this channel prevents closure,
so that the β cell remains hyperpolarized and unable to
secrete insulin. Evaluation of the specific mutations
resulting in PNDM is imperative, as patients with
KCNJ11 mutations can be safely and effectively mana-
ged with oral sulfonylurea therapy [9]. Failure to appro-
priately diagnose these patients may result in
unnecessary lifelong therapy with subcutaneous insulin.
Emerging knowledge of the mutations underlying
PNDM and TNDM has improved our capacity to pro-
vide genetic counseling to affected families. While most
mutations causing PLAGL1 overexpression are due to
de novo events such as methylation defects or segmental
uniparental disomy, microduplications can be inherited
in an autosomal dominant, imprinting-type, manner
[7,10,11]. In families with this imprinting type of NDM,
like our case, overexpression of PLAGL1 only occurs
when the microduplication is passed through the male
germ line, since passage through the maternal germ line
will inactivate both copies of PLAGL1 via methylation of
its promoter [12,13]. Dominant imprinting inheritance
was supported in our family by the observation that the
patient’s father and his brother (the paternal uncle) both
carried the duplication but were asymptomatic. How-
ever, in the grandparental generation, the paternal
grandmother had neonatal DM, presumably indicating
that she carried the duplication.
Despite improved understanding of the genetic basis
for NDM, diagnosis of NDM has historically been a
post-partum event based on the unexpected develop-
ment of persistent hyperglycemia in a neonate. Genetictesting is typically performed well after initiation of insu-
lin, with results often reported after discharge from the
nursery. The potential to diagnose these mutations pre-
natally, as occurred with our patient’s cousin, may
greatly improve the management of TNDM by allowing
families and physicians to be optimally prepared for the
development of hyperglycemia. Only recently has uni-
parental disomy of paternal chromosome 6 been
detected through amniocentesis [14].
Finally, the combination of CDH and TNDM has not
previously been reported. A review of diaphragmatic
hernia genomic etiologies did not implicate the 6q24.2
locus [15]. However, CDH has been reported in associ-
ation with numerous extra-diaphragmatic abnormalities
including gut malrotation, umbilical hernia, hydrone-
phrosis, cardiac defects, and type 1 diabetes. CDH is also
a common feature of Beckwith-Wiedemann syndrome
(BWS), another imprinted genetic disorder that, like
TND, may be associated with macroglossia and umbil-
ical hernia [16]. The known association of CDH and
extra-diaphragmatic abnormalities suggests that a com-
mon genetic or embryologic etiology might underlie
CDH and TNDM.Conclusions
This case provided the opportunity to demonstrate the
successful use of CSII in the management of TNDM
complicated by a concurrent congenital anomaly. In
addition, this case models the potential value of genetic
counseling and prenatal diagnosis in families affected by
NDM. Given the incidence of TNDM and CDH, the
likelihood of a child presenting with both CDH and
TNDM is approximately 1 in 1,250,000,000. While a re-
view a review of diaphragmatic hernia genomic etiolo-
gies did not implicate the 6q24.2 locus, our case either
represents the observation of an extremely rare coinci-
dental event or indicates that there is a potential link be-
tween TNDM and CDH. Further examination of loci
neighboring the 6q24 region, and their role in organo-
genesis, may provide insights toward explaining our
patient’s development of two uncommon diagnoses.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.Additional file
Additional file 1: Pertinent physical findings in our patient included
shallow supraorbital ridges, relatively prominent eyes, a mildly protruding
tongue with micrognathia, mild pectus excavatum, and bilateral
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nevus flammeus, normal ears without pits, and no evidence of limb
asymmetry.
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